08048035968
CANMAB 440MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

Canmab 440mg Injection is a trastuzumab-based targeted cancer medicine. Trastuzumab specifically binds to the HER2 protein, which can be present in unusually high amounts on certain cancer cells. By interfering with HER2 signaling and promoting immune-mediated destruction of HER2-positive cells, trastuzumab can help slow cancer growth.

It is a prescription-only injectable biologic and is not intended for self-administration.

2. Product Information

  • Brand: Canmab 440mg Injection
  • Active ingredient: Trastuzumab
  • Strength: 440mg
  • Dosage form: Lyophilized powder for injection
  • Drug class: Monoclonal antibody / targeted cancer therapy
  • Manufacturer: Biocon
  • Route: Intravenous infusion, when prescribed in the appropriate formulation
  • Storage: Trastuzumab products require appropriate cold-chain handling. Canmab 440mg is generally stored under refrigerated conditions; follow the product label and manufacturer instructions.
  • Prescription: Required

The exact formulation, presentation and approved indications can vary by country, so the local product label should always be checked.

3. Uses of Canmab 440mg Injection

Canmab 440mg may be prescribed for cancers in which the tumor demonstrates HER2 overexpression/amplification, including:

HER2-positive breast cancer

It may be used in appropriate patients with early-stage or metastatic HER2-positive breast cancer, either alone or alongside other anticancer treatments according to the oncologist's treatment plan.

HER2-positive gastric cancer

Trastuzumab may also be used with chemotherapy for appropriately selected patients with advanced HER2-positive gastric or gastroesophageal-junction cancer.

HER2 status should be confirmed using appropriate diagnostic testing before treatment.

4. Benefits of This Medicine

Potential clinical benefits of trastuzumab therapy include:

  • Provides targeted treatment against HER2-positive cancer cells.
  • Blocks HER2-mediated signals that can promote cancer-cell growth.
  • Can help slow progression of HER2-positive cancers.
  • May improve disease control when used as part of an appropriate treatment regimen.
  • Can be combined with chemotherapy or other cancer treatments when clinically indicated.
  • Provides a targeted therapeutic option for eligible patients with HER2-positive breast or gastric cancer.

The expected benefit varies according to cancer type, stage, HER2 status, previous treatment and the overall treatment plan.

5. Side Effects of Canmab 440mg Injection

Like other trastuzumab products, Canmab may cause adverse effects. Some reactions can occur during or shortly after infusion, while others may develop during treatment.

Important potential adverse effects include:

  • Infusion-related reactions
  • Fever and chills
  • Nausea or vomiting
  • Diarrhea
  • Headache
  • Fatigue
  • Cough or shortness of breath
  • Rash
  • Infections
  • Reduced blood-cell counts
  • Cardiac dysfunction or heart failure
  • Serious hypersensitivity reactions
  • Pulmonary toxicity

Trastuzumab carries important warnings concerning cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

6. Common Side Effects

Commonly reported adverse reactions with trastuzumab-based treatment can include:

  • Fever
  • Chills
  • Headache
  • Nausea
  • Vomiting
  • Diarrhea
  • Fatigue
  • Cough
  • Rash
  • Muscle or joint pain
  • Infusion reactions
  • Increased risk of infections
  • Anemia or other blood-count abnormalities

The frequency and severity can differ depending on the cancer being treated and whether trastuzumab is administered with chemotherapy or other medicines.

7. How to Use Canmab 440mg Injection

Canmab 440mg Injection should be administered only by a qualified healthcare professional.

The oncologist determines the dose and treatment schedule based on factors such as:

  • Cancer type and stage
  • HER2 test results
  • Body weight
  • Previous treatments
  • Other medicines being administered
  • Cardiac function and overall health

Trastuzumab is administered by intravenous infusion, with dosing schedules varying according to the indication and treatment regimen. For example, approved trastuzumab regimens can include weight-based loading and maintenance doses given weekly or every three weeks.

Do not attempt to inject or administer Canmab yourself. The product should be prepared and administered according to the approved product information.

8. How Canmab 440mg Works

Canmab contains trastuzumab, which is designed to recognize and bind to HER2 (human epidermal growth factor receptor 2).

Some cancer cells have excessive HER2 activity, which can contribute to uncontrolled cell growth. Trastuzumab binds to HER2 and interferes with HER2 signaling. It can also help the immune system recognize and attack HER2-expressing cancer cells.

Therefore, Canmab is considered a targeted biological therapy, rather than a conventional nonspecific chemotherapy medicine.

9. Safety Advice for Canmab 440mg

  • Use Canmab only under the supervision of an oncologist.
  • HER2 status should be appropriately evaluated before treatment.
  • Cardiac function should be assessed before and during trastuzumab therapy because treatment can cause decreased left-ventricular function and heart failure.
  • Inform the doctor about any previous heart problems.
  • Report breathing difficulties, severe chills, fever, dizziness, swelling or other serious symptoms immediately.
  • Serious infusion reactions can occur during or shortly after administration.
  • Trastuzumab may cause fetal harm; pregnancy status and contraception requirements should be discussed with the treating physician.
  • Tell the oncologist about all medicines and cancer treatments being taken.
  • Maintain the required cold-chain conditions during storage and transportation.
  • Do not freeze the medicine unless the approved product information specifically permits it.
  • Do not use a damaged, improperly stored or expired vial.
  • International shipment and import should comply with the pharmaceutical regulations of the destination country.

10. Frequently Asked Questions (FAQs)

Q1. What is Canmab 440mg Injection?

Canmab 440mg Injection is a trastuzumab-containing targeted biological medicine used for certain HER2-positive cancers.

Q2. What is the active ingredient in Canmab?

The active ingredient is trastuzumab.

Q3. What is Canmab 440mg used for?

It is used for appropriately selected patients with HER2-positive breast cancer and certain advanced HER2-positive gastric or gastroesophageal-junction cancers.

Q4. Is Canmab a chemotherapy medicine?

Canmab is a targeted monoclonal antibody therapy, not a conventional cytotoxic chemotherapy medicine. It may nevertheless be prescribed together with chemotherapy depending on the treatment plan.

Q5. Is Canmab 440mg available as a prescription medicine?

Yes. It is a prescription cancer medicine and should be used only under specialist medical supervision.

Q6. Does Canmab require refrigeration?

Yes. Trastuzumab products require controlled refrigerated storage and appropriate cold-chain handling. Follow the specific manufacturer's storage instructions.

Q7. Can Canmab be self-administered?

No. It should be prepared and administered by trained healthcare professionals.

Q8. Does Canmab affect the heart?

Trastuzumab can cause decreased cardiac function and, in some patients, heart failure. Cardiac monitoring is therefore an important part of treatment.

Q9. What are the common side effects?

Fever, chills, headache, nausea, diarrhea, fatigue, cough, rash and infusion-related reactions are among the reported adverse effects.

Q10. Can Canmab be used during pregnancy?

Trastuzumab can cause fetal harm and is generally avoided during pregnancy unless specifically determined otherwise by the treating specialist. Pregnancy and contraception should be discussed with the oncologist.

11. Substitutes for Canmab 440mg Injection

The appropriate substitute depends on the patient's clinical condition, HER2 status, treatment protocol, country and product availability. Trastuzumab biosimilars may be considered by an oncologist where approved and appropriate.

Examples of trastuzumab products/biosimilars in different markets include:

  • Herceptin (trastuzumab)
  • Ogivri (trastuzumab-dkst)
  • Trazimera (trastuzumab-qyyp)
  • Kanjinti (trastuzumab-anns)
  • Herzuma (trastuzumab-pkrb)

These products are not automatically interchangeable in every country or clinical situation. A doctor or pharmacist should confirm the appropriate product before substitution.

12. SEO & B2B Keywords

Primary Keywords:

  • Canmab 440mg Injection
  • Canmab 440mg Injection exporter
  • Canmab 440mg Injection supplier
  • Canmab 440mg Injection wholesale
  • Canmab 440mg Injection manufacturer
  • Trastuzumab 440mg Injection
  • Trastuzumab 440mg exporter from India
  • Trastuzumab 440mg supplier India
  • Canmab 440mg pharmaceutical exporter
  • Canmab 440mg medicine exporter

Long-Tail B2B Keywords:

  • Canmab 440mg Injection supplier from India
  • Canmab 440mg Injection exporter from Nagpur India
  • Canmab 440mg wholesale pharmaceutical supplier India
  • Trastuzumab 440mg Injection international supplier
  • Canmab 440mg Injection bulk supply from India
  • Canmab 440mg Injection for international pharmaceutical procurement
  • Genuine Canmab 440mg Injection pharmaceutical supplier
  • Canmab 440mg Injection cold chain supplier India
  • Canmab 440mg Injection export supplier for USA
  • Canmab 440mg Injection export supplier for UK
  • Canmab 440mg Injection supplier for Australia
  • Canmab 440mg Injection supplier for Canada
  • Canmab 440mg Injection supplier for Singapore
  • Canmab 440mg Injection supplier for South Korea
  • Canmab 440mg Injection supplier for UAE
  • Trastuzumab 440mg oncology medicine exporter India
  • HER2 targeted therapy pharmaceutical supplier India
  • HER2 positive cancer medicine exporter from India
  • Oncology medicine exporter from Nagpur India
  • Biologic cancer medicine supplier from India
Aug 22nd, 2026 12:57 PM

Keywords